Catalyst Wire Dossier Catalyst Wire Dossier

CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy

· Caribou Biosciences, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy, covering 2025-09-25 to 2025-09-25. Get the full timeline:

Most recent: Clinical Trial Update: CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

See pricing